239,861 Shares in Erasca, Inc. $ERAS Bought by Stempoint Capital LP

Stempoint Capital LP bought a new stake in shares of Erasca, Inc. (NASDAQ:ERAS) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 239,861 shares of the company’s stock, valued at approximately $3,881,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ERAS. AQR Capital Management LLC grew its stake in shares of Erasca by 594.8% during the first quarter. AQR Capital Management LLC now owns 396,202 shares of the company’s stock worth $543,000 after acquiring an additional 339,177 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Erasca by 1.6% during the second quarter. Geode Capital Management LLC now owns 4,835,642 shares of the company’s stock valued at $6,143,000 after acquiring an additional 77,790 shares in the last quarter. Creative Planning raised its position in shares of Erasca by 423.3% in the 2nd quarter. Creative Planning now owns 244,332 shares of the company’s stock valued at $310,000 after purchasing an additional 197,637 shares during the last quarter. New York State Common Retirement Fund raised its position in shares of Erasca by 39.1% in the 2nd quarter. New York State Common Retirement Fund now owns 37,360 shares of the company’s stock valued at $47,000 after purchasing an additional 10,501 shares during the last quarter. Finally, Invesco Ltd. boosted its stake in Erasca by 51.6% in the 2nd quarter. Invesco Ltd. now owns 172,226 shares of the company’s stock worth $219,000 after purchasing an additional 58,643 shares in the last quarter. 67.78% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Erasca

Here are the key news stories impacting Erasca this week:

• Neutral Sentiment: Multiple law firms reminded shareholders that August 10, 2026 is the deadline to seek appointment as lead plaintiff in a pending securities class action covering investors who purchased Erasca shares between January 14, 2025, and April 26, 2026. Berger Montague class-action reminder
• Negative Sentiment: The lawsuits allege that Erasca and certain executives misled investors about ERAS-0015’s competitive advantages, safety profile, and intellectual-property protection. These allegations could lead to legal expenses, potential damages, and additional scrutiny, although they remain unproven. Hagens Berman Erasca investor deadline
• Negative Sentiment: One notice describes a 15-month sequence involving statements at a J.P. Morgan conference, a patent-infringement letter, and a reported patient death, claiming these events contributed to investor losses of $11.59 per share. Levi and Korsinsky Erasca class-action notice
• Negative Sentiment: Another investor alert says a $258.8 million stock offering preceded a 53.9% share-price collapse, raising concerns about alleged disclosure issues and potential recovery claims. SueWallSt Erasca shareholder alert

Analysts Set New Price Targets

Several analysts have weighed in on the stock. Wall Street Zen downgraded shares of Erasca from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Erasca in a report on Tuesday, July 14th. Bank of America lifted their price objective on shares of Erasca from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Tuesday, July 14th. HSBC set a $20.00 price objective on shares of Erasca in a report on Tuesday, July 14th. Finally, Morgan Stanley raised their target price on Erasca from $12.00 to $21.00 and gave the stock an “equal weight” rating in a research note on Monday, July 20th. Eight analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Erasca currently has an average rating of “Moderate Buy” and a consensus price target of $21.64.

Erasca Stock Down 2.4%

Shares of NASDAQ ERAS opened at $17.72 on Thursday. The business’s 50 day moving average price is $15.90 and its 200 day moving average price is $14.27. The firm has a market cap of $5.51 billion, a P/E ratio of -19.05 and a beta of 0.66. Erasca, Inc. has a 52 week low of $1.33 and a 52 week high of $24.28.

Erasca (NASDAQ:ERAS) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.48). As a group, research analysts expect that Erasca, Inc. will post -0.54 earnings per share for the current year.

Erasca Profile

Erasca, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of precision medicines for patients with cancer. The company focuses on small molecule therapeutics that target critical signaling pathways involved in tumor growth and survival, with a primary emphasis on inhibitors of the MAPK pathway. Erasca’s approach is designed to deliver oral, targeted therapies that address both oncogene‐driven and immuno‐oncology indications, aiming to improve outcomes for patients with unmet medical needs.

Erasca’s pipeline comprises multiple development candidates, including small molecule inhibitors engineered to disrupt key nodes in cancer cell signaling.